Taysha Gene Therapies, Inc. (TSHA) stock
TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.00−0.06 (-1.48%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Taysha Gene Therapies price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Taysha Gene Therapies's price to sales ratio was 253.8× on Nov 11, 2026, against 205.8× a year earlier. Over the last 3 years it ranged from 26.4× to 337.5×, with a median of 77.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 253.8× | +15.1 |
| 2025 | Dec 31, 2025 | 238.8× | +203.0 |
| 2024 | Dec 31, 2024 | 35.8× | – |
See a number that looks wrong?